Popular Articles

Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population.
buy viagra
VIA Pharmaceuticals Announces Complete Enrollment In FDG-PET Phase 2 Study Of VIA-2291 In Cardiovascular Patients
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in patients who have experienced an acute coronary syndrome event such as a heart attack or unstable angina. The randomized, double blind, placebo-controlled study examines the impact of VIA-2291 on plaque inflammation as measured by Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET), as well as other standard biomarkers of inflammation, over 24 weeks following such an acute event. A total of 52 patients have been enrolled in the study, which is expected to report data in the second half of 2009.
plan for health
News of the day
Meeting To Examine Human Behavior And The Threat Of Disease
As swine flu spread from Mexico to Texas and then fanned out farther in the United States, Americans began to alter their behavior. Families kept children home from school, postponed trips to the mall, and stayed home instead of eating out. In so doing, the American population may have inadvertently altered the behavior of the pathogen itself.
Cardiovascular

Presentation At AAPM Meeting On Nanoparticles That Package Cancer-killing Isotopes And Deliver Them Into Cancer Cells

A group of researchers at Johns Hopkins University has designed nanoparticles that can carry cancer-treating radioisotopes through the body and deliver them selectively to tumors. Today in Anaheim, CA, they will report the latest results of their research, including studies in animal models, at the 51st meeting of the American Association of Physicists in Medicine (AAPM). The nanoparticles are made with a commercially available product known as "liposomes" -- small chemical spheres made of fatty molecules that can package drugs and other chemicals. Liposomes are a powerful emerging tool in medicine because they can be designed to carry many different drugs and manipulated to control how long they stay in the bloodstream. One type of liposome, Doxil, is already approved by the U.S. Food and Drug Administration (FDA) for delivering Doxorubicin, a chemotherapeutic that is toxic to the heart. The Hopkins scientists are using liposomes that have been modified with antibodies, a class of immune system proteins that recognize and bind to many different microscopic targets -- bacteria, viruses, other proteins, and human cells. Some antibodies specifically bind to cancer cells, and by attaching these cancer-specific antibodies to the liposomes, the scientists have created "immunoliposomes," which will wend their way through the bloodstream and seek out tumors inside the body. When they come into contact with their target cells, they deliver their payload into the cells. "It"s a promising approach to solving the problem of how to deliver more of a therapeutic to cancer cells," says George Sgouros, a radiology professor at Johns Hopkins who led the research. Similar studies by other groups of researchers have already demonstrated how immunoliposomes could be packaged with tiny radioactive tracers used for imaging tumors. What Sgouros and his colleagues have done is figure out how to reproducibly package much more powerful radioisotopes, called alpha-particle emitters that have the ability to kill cancer cells without damaging nearby normal cells, and they have tested how effectively they can treat mice with a very aggressive type of metastatic breast cancer. Early results show that they can pack a relatively large dose of radionuclides into the liposomes and substantially extend the life of treated mice. "This treatment is much less toxic than chemotherapy because it is targeted to tumor cells rather than to all rapidly dividing cells " says Sgouros. "Nanoparticles designed to deliver these powerful isotopes have a great potential in cancer therapy, particularly for metastatic disease." ABOUT MEDICAL PHYSICISTS If you ever had a mammogram, ultrasound, X-ray, MRI, PET scan, or known someone treated for cancer, chances are reasonable that a medical physicist was working behind the scenes to make sure the imaging procedure was as effective as possible. Medical physicists help to develop new imaging techniques, improve existing ones, and assure the safety of radiation used in medical procedures in radiology, radiation oncology and nuclear medicine. They collaborate with radiation oncologists to design cancer treatment plans. They provide routine quality assurance and quality control on radiation equipment and procedures to ensure that cancer patients receive the prescribed dose of radiation to the correct location. They also contribute to the development of physics intensive therapeutic techniques, such as the stereotactic radiosurgery and prostate seed implants for cancer to name a few. The annual AAPM meeting is a great re, providing guidance to physicists to implement the latest and greatest technology in a community hospital close to you. ABOUT AAPM The American Association of Physicists in Medicine (AAPM) is a scientific, educational, and professional organization of more than 6,000 medical physicists. Headquarters are located at the American Center for Physics in College Park, MD. Publications include a scientific journal ("Medical Physics"), technical reports, and symposium proceedings. American Institute of Physics (AIP)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):